AR 0 6 ES Docket No.: PF-0459 US

I hereby certified at this correspondence is being deposited with the Alnited States ostal Service as first class mail in an envelope of Assistant Commissioner for Patents.

Washington, D.C. 20231 on \_\_\_\_\_\_\_4]/ 98

Printed: VEANATE 6 - LAB

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title:

**HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS** 

Serial No.:

09/002,485

Filing Date:

December 31, 1997

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Assistant Commissioner for Patents

Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Docket No.: PF-0459 US

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this communication is enclosed.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date:

Sheela Mohan-Peterson

Reg. No. 41,201

3174 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166